{"organizations": [], "uuid": "069f3c9cd27d1ce89006732c2104b09c38453c4a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-portola-pharmaceuticals-announces/brief-portola-pharmaceuticals-announces-new-interim-results-from-ongoing-annexa-4-study-idUSFWN1QU0Z0", "country": "US", "domain_rank": 408, "title": "BRIEF-Portola Pharmaceuticals Announces New Interim Results From Ongoing Annexa-4 Study", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-12T18:17:00.000+02:00", "replies_count": 0, "uuid": "069f3c9cd27d1ce89006732c2104b09c38453c4a"}, "author": "", "url": "https://www.reuters.com/article/brief-portola-pharmaceuticals-announces/brief-portola-pharmaceuticals-announces-new-interim-results-from-ongoing-annexa-4-study-idUSFWN1QU0Z0", "ord_in_thread": 0, "title": "BRIEF-Portola Pharmaceuticals Announces New Interim Results From Ongoing Annexa-4 Study", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "brief-portola pharmaceuticals announces new interim", "sentiment": "negative"}, {"name": "brief-portola pharmaceuticals", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "portola pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 12, 2018 / 4:20 PM / Updated 7 minutes ago BRIEF-Portola Pharmaceuticals Announces New Interim Results From Ongoing Annexa-4 Study Reuters Staff 1 Min Read March 12 (Reuters) - Portola Pharmaceuticals Inc: * PORTOLA PHARMACEUTICALS ANNOUNCES NEW INTERIM RESULTS FROM ONGOING ANNEXA-4 STUDY OF FACTOR XA INHIBITOR REVERSAL AGENT ANDEXXAÂ® (ANDEXANET ALFA) IN PATIENTS WITH LIFE-THREATENING BLEEDING * PORTOLA PHARMACEUTICALS INC - THE INTERIM RESULTS INCLUDED SAFETY DATA FROM 227 OF 228 ENROLLED PATIENTS * PORTOLA PHARMACEUTICALS INC - EXCELLENT OR GOOD HEMOSTASIS ACHIEVED IN 83 PERCENT OF PATIENTS IN ANNEXA-4 * PORTOLA PHARMACEUTICALS INC - ANDEXANET ALFA IS CURRENTLY UNDER REVIEW BY U.S. FDA WITH AN ASSIGNED ACTION DATE OF MAY 4, 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-12T18:17:00.000+02:00", "crawled": "2018-03-12T18:36:56.047+02:00", "highlightTitle": ""}